Global Hospital Acquired Disease Testing Market Report 2018: $1.72 Billion Market Trends, Share, Size, Growth, Opportunity and Forecasts 2017-2023

Dublin, Jan. 11, 2019 (GLOBE NEWSWIRE) -- The "Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023" report has been added to's offering.

The global hospital acquired disease testing market was worth US$ 752 Million in 2017

A major reason behind the cause of hospital acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Another reason can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patients' own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.

The market for hospital acquired disease testing is currently exhibiting double digit growth rates. Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests.

Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market.

Looking forward, the market value is projected to exceed US$ 1,720 Million by 2023, exhibiting a CAGR of around 18% during 2018-2023.

Key Questions Answered in This Report:

  • How has the global hospital acquired disease testing market performed so far and how will it perform in the coming years?
  • What are the key regional markets in the global hospital acquired disease testing industry?
  • What is the breakup of the global hospital acquired disease market on the basis of indication?
  • What are the various stages in the value chain of the global hospital acquired disease testing market?
  • What are the key driving factors and challenges in the global hospital acquired disease testing market?
  • What is the structure of the global hospital acquired disease testing market and who are the key players?
  • What is the degree of competition in the global hospital acquired disease testing market?

Key Topics Covered:

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.4 Market Estimation
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Hospital Acquired Disease Testing Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Indication
5.4 Market Breakup by Region
5.5 Market Forecast
5.6 SWOT Analysis
5.7 Value Chain Analysis
5.8 Porters Five Forces Analysis
5.9 Price Analysis

6 Market Breakup by Indication
6.1 UTI (Urinary Tract Infection)
6.2 SSI (Surgical Site Infection)
6.3 Pneumonia
6.4 Bloodstream Infections
6.5 MRSA (Methicillin-Resistant Staphylococcus Aureus)
6.6 Others

7 Market Breakup by Region
7.1 North America
7.2 Europe
7.3 Asia Pacific
7.4 Middle East and Africa
7.5 Latin America

8 Competitive Landscape
8.1 Market Structure
8.2 Key Players
8.3 Profiles of Key Players
8.3.1 Abbott Laboratories
8.3.2 Alere, Inc.
8.3.3 Becton, Dickinson and Company
8.3.4 bioMrieux SA
8.3.5 F. Hoffmann-La Roche Ltd.
8.3.6 Hologic, Inc.
8.3.7 QIAGEN
8.3.8 Siemens Healthcare
8.3.9 Diatherix Laboratories, Inc.
8.3.10 Meridian Bioscience, Inc.
8.3.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
8.3.12 Cepheid, Inc.

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

         Laura Wood, Senior Press Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Disease Testing